Technical Analysis for 0QNA - Basilea Pharmaceutica AG
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 40.60 | 0.87% | 0.35 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.87% | |
| Stochastic Reached Oversold | Weakness | 0.87% | |
| Down 3 Days in a Row | Weakness | 0.87% | |
| Oversold Stochastic | Weakness | 0.87% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.12% | |
| NR7 | Range Contraction | 0.12% | |
| NR7-2 | Range Contraction | 0.12% |
| Alert | Time |
|---|---|
| Possible NR7 | about 22 hours ago |
| Fell Below Previous Day's Low | 2 days ago |
| Fell Below 20 DMA | 2 days ago |
| Possible Inside Day | 2 days ago |
| Possible NR7 | 2 days ago |
Get a Trading Sidekick!
Basilea Pharmaceutica AG Description
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Classification
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 49.0 |
| 52 Week Low | 32.2 |
| Average Volume | 3,991 |
| 200-Day Moving Average | 38.87 |
| 50-Day Moving Average | 38.18 |
| 20-Day Moving Average | 40.68 |
| 10-Day Moving Average | 41.06 |
| Average True Range | 0.95 |
| RSI (14) | 55.36 |
| ADX | 27.22 |
| +DI | 25.88 |
| -DI | 18.13 |
| Chandelier Exit (Long, 3 ATRs) | 40.60 |
| Chandelier Exit (Short, 3 ATRs) | 39.70 |
| Upper Bollinger Bands | 43.77 |
| Lower Bollinger Band | 37.59 |
| Percent B (%b) | 0.49 |
| BandWidth | 15.19 |
| MACD Line | 0.86 |
| MACD Signal Line | 1.10 |
| MACD Histogram | -0.237 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.13 | ||||
| Resistance 3 (R3) | 41.07 | 40.84 | 41.04 | ||
| Resistance 2 (R2) | 40.84 | 40.70 | 40.87 | 41.01 | |
| Resistance 1 (R1) | 40.72 | 40.62 | 40.78 | 40.78 | 40.98 |
| Pivot Point | 40.48 | 40.48 | 40.51 | 40.51 | 40.48 |
| Support 1 (S1) | 40.36 | 40.35 | 40.42 | 40.42 | 40.22 |
| Support 2 (S2) | 40.13 | 40.26 | 40.16 | 40.19 | |
| Support 3 (S3) | 40.01 | 40.13 | 40.16 | ||
| Support 4 (S4) | 40.07 |
